1 newer ruling cite the same tariff codes.

Classification can shift over time. Review the more recent rulings below before relying on this one.

E86579 E8 Ruling Active

The tariff classification of Actinase AS (CAS-9001-92-7) from Japan

Issued September 20, 1999 by U.S. Customs and Border Protection.

Cite this ruling

Copies to clipboard

E8 E86579 (September 20, 1999)

Tariff classification

HTS codes: 3002.10.0090

Headings: 3002

Product description

The subject product, which you refer to as “Actinase AS,” is referred to in The Merck Index, 12th Edition, as Factor XIII, Blood-coagulation factor XIII, and factor XIII. It is also known as fibrin stabilizing factor (FSF), fibrinase, and Laki-Lorand factor (LLF). According to The Merck Index, 12th Edition, factor XIII is a plasma enzyme precursor which, upon activation by the enzyme, thrombin (in the presence of calcium ions), converts soluble fibrin gel to an insoluble clot.

CBP rationale

The applicable subheading for the subject product will be 3002.10.0090, Harmonized Tariff Schedule of the United States (HTS), which provides for "{A]ntisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes: Other.

Full text

NY E86579 September 20, 1999 CLA-2-30:RR:NC:2:238 E86579 CATEGORY: Classification TARIFF NO.: 3002.10.0090 Mr. Joseph J. Chivini Austin Chemical Company, Inc. 1565 Barclay Boulevard Buffalo Grove, IL 60089 RE: The tariff classification of Actinase AS (CAS-9001-92-7) from Japan Dear Mr. Chivini: In your letter dated August 23, 1999, you requested a tariff classification ruling. The subject product, which you refer to as “Actinase AS,” is referred to in The Merck Index, 12th Edition, as Factor XIII, Blood-coagulation factor XIII, and factor XIII. It is also known as fibrin stabilizing factor (FSF), fibrinase, and Laki-Lorand factor (LLF). According to The Merck Index, 12th Edition, factor XIII is a plasma enzyme precursor which, upon activation by the enzyme, thrombin (in the presence of calcium ions), converts soluble fibrin gel to an insoluble clot. The applicable subheading for the subject product will be 3002.10.0090, Harmonized Tariff Schedule of the United States (HTS), which provides for "{A]ntisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes: Other." The rate of duty will be free. This merchandise may be subject to the requirements of the Federal Food, Drug, and Cosmetic Act, which is administered by the U.S. Food and Drug Administration. You may contact them at 5600 Fishers Lane, Rockville, Maryland 20857, telephone number 301-443-1544. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 212-637-7068. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

Follow E86579

Get an email if this ruling is revoked or modified, or a newer ruling supersedes it.

One email per day at most. Confirm your address once, unsubscribe anytime.

Searching CBP rulings the smart way

Rulings are precedent. See which ones apply to your product: TariffLens semantically searches all 200,000+ CBP rulings and builds defensible classifications backed by ruling citations.